Shares of CStone Pharmaceuticals-B (02616) climbed more than 6% in morning trading. At the time of writing, the stock was up 6.12% to HK$4.68, with a turnover of HK$4.4857 million.

The recent price movement follows an announcement from CStone regarding an exclusive commercialization partnership for its drug sugemalimab in Australia and New Zealand. The company has entered into an agreement with Arrotex Pharmaceuticals Pty Ltd, a core pharmaceutical commercialization platform under the Australian integrated healthcare group DBG Health.

Under the terms of the deal, CStone is set to receive an upfront payment from Arrotex, along with additional potential milestone payments tied to regulatory progress and sales achievements. CStone will be responsible for supplying sugemalimab to Arrotex and will also receive a share of the profits generated within the licensed territory.

Scope of the Commercial Rights

Arrotex has secured exclusive commercialization rights for sugemalimab in Australia and New Zealand. These rights encompass all currently approved indications as well as potential future ones, which include stage III and IV non-small cell lung cancer (NSCLC), gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), and extranodal NK/T-cell lymphoma (ENKTL). It is noted that approval for some of these indications from Australian regulatory authorities is still pending.

Responsibilities Under the Agreement

Arrotex will undertake the regulatory submission processes and lead all commercialization and promotional activities for sugemalimab within the designated regions.